{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.57
Lipocine, Inc. has reached a new 52-week low, reflecting significant challenges in its financial performance. The company has seen a substantial decline in net sales and a negative return on equity, alongside a decrease in institutional investor participation, indicating a precarious financial situation in the Pharmaceuticals & Biotechnology sector.
Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.65
Lipocine, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company faces challenges with negative return on equity, a sharp drop in net sales, and consecutive quarterly losses, alongside reduced institutional investor participation.
Lipocine, Inc. Hits New 52-Week Low at $2.68 Amid Declining Sales
Lipocine, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant decline in stock price and net sales. The company faces ongoing financial challenges, including negative returns on equity and reduced institutional investor participation, contributing to heightened market risk perceptions.
Is Lipocine, Inc. technically bullish or bearish?
As of September 8, 2025, Lipocine, Inc. is in a mildly bearish trend, indicated by bearish MACD and moving averages, and has underperformed the S&P 500 with a year-to-date return of -42.42%.
Is Lipocine, Inc. overvalued or undervalued?
As of May 8, 2025, Lipocine, Inc. is considered a risky investment due to its overvaluation and poor performance metrics, including a Price to Book Value of 0.88 and significant underperformance against the S&P 500, with a year-to-date return of -42.42%.
Is Lipocine, Inc. overvalued or undervalued?
As of May 8, 2025, Lipocine, Inc. is considered overvalued and has a risky valuation grade due to poor financial metrics, a Price to Book Value of 0.88, an EV to EBITDA of 0.43, and a year-to-date stock performance of -35.66%, significantly underperforming the S&P 500.
Is Lipocine, Inc. technically bullish or bearish?
As of May 15, 2025, Lipocine, Inc. is in a mildly bearish trend due to bearish daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the MACD and OBV.
Who are in the management team of Lipocine, Inc.?
As of March 2022, Lipocine, Inc.'s management team includes Dr. Mahesh Patel as Chairman, President, and CEO, with Dr. Stephen Hill as Lead Independent Director, and board members Mr. John Higuchi, Mr. Jeffrey Fink, and Dr. Richard Ono.
What does Lipocine, Inc. do?
Lipocine, Inc. is a clinical-stage biopharmaceutical company specializing in oral drug delivery technologies. As of March 2025, it has a market cap of $16.79 million, with net sales of $0 million and a net loss of $2 million.
How big is Lipocine, Inc.?
As of Jun 18, Lipocine, Inc. has a market capitalization of 16.79 million, with net sales of 3.67 million and a net profit of -5.37 million over the latest four quarters. The company reported shareholder's funds of 21.00 million and total assets of 22.51 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
